The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Buck up, baby boomers. Sixty may not be the new 40, but 80 could soon be the new 60. A trove of new Alzheimer’s research ...

With consumers struggling to differentiate between credible and unreliable medical information online, Medistry LLC's premium .med Top Level Domain (TLD) is poised to help.

The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in ...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path ...

Denali Therapeutics (DNLI) reported a second-quarter 2025 loss of 72 cents per share, narrower than the Zacks Consensus Estimate of a loss of 74 cents. The company reported a loss of 59 cents in the ...

Denali Therapeutics ( ($DNLI) ) has released its Q2 earnings. Here is a breakdown of the information Denali Therapeutics presented to its ...

According to the latest study from BCC Research, the "Global Irritable Bowel Syndrome and Inflammatory Bowel Disease ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This whitepaper will show leaders how strategic insights and targeted outreach can turn ...

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today ...